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Abstract
Haemophilus influenzae type b (Hib) is now recognized as an important pathogen in Asia. To evaluate disease susceptibility,
and as a marker of Hib transmission before routine immunization was introduced in Kathmandu, 71 participants aged 7
months–77 years were recruited and 15 cord blood samples were collected for analysis of anti-polyribosylribitol phosphate
antibody levels by enzyme-linked immunosorbent assay. Only 20% of children under 5 years old had levels considered
protective (.0.15 mg/ml), rising to 83% of 15–54 year-olds. Prior to introduction of Hib vaccine in Kathmandu, the majority
of young children were susceptible to disease.
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Introduction
Haemophilus influenzae type b (Hib) remains a significant cause of
invasive bacterial disease globally, and is of particular importance
in resource-poor countries. It is estimated to cause approximately
371,000 deaths each year and over 8 million cases of serious
disease in children under 5, including pneumonia, meningitis and
epiglottitis [1]. The Hib vaccine comprises the Hib surface
polysaccharide antigen polyribosylribitol phosphate (PRP) conju-
gated to a protein carrier. Since 2006, the World Health
Organization (WHO) has recommended that this vaccine be
included in all routine infant immunization programmes [2]. The
WHO advised that ‘‘lack of local surveillance data should not
delay the introduction of these vaccines’’, especially in countries
with evidence of a high burden of disease. Despite this, uncertainty
has surrounded the relative importance of Hib disease in South
East Asia, and adoption of the vaccine has subsequently been slow
[3]. With support from the Global Alliance for Vaccines and
Immunization, Hib vaccine was introduced in Nepal in 2009 [4].
In unvaccinated populations, repeated exposure to Hib antigens
during childhood is thought to lead to natural immunity, with
development of protective levels of anti-PRP antibody over time
[5]. The aim of this seroepidemiological study, carried out in the
pre-Hib-vaccination era in Nepal, was to determine the level of
Hib-specific serum antibodies in a sample of the Kathmandu
population, in order to evaluate disease susceptibility, and as a
surrogate marker of Hib transmission prior to vaccine introduc-
tion. In addition these data may provide a useful baseline against
which to compare post-vaccination seroepidemiological studies,
for example when determining whether a booster vaccine dose will
be needed in this population [6].
Materials and Methods
Ethics statement
As part of the original study [7], ethical approval was given by
the appropriate Institutional Review Boards (The Nepal Health
Research Council and the Oxford Tropical Research Ethics
Committee, reference 017-05) for sample storage and use in future
studies of vaccine-related immunity. Written consent was provided
by all participants or the parents/guardians for those under the
age of 18 years.
Participants and samples
The samples were collected as part of a seroepidemiological
study described previously [7]. Briefly, patients attending the
outpatient department at Patan Hospital, Kathmandu, Nepal, for
non-infectious conditions in June and July 2006 were invited to
participate. Hib vaccine was available in some private clinics in
Nepal at the time, but in practice unavailable to the vast majority
of patients attending Patan Hospital. Following fully informed
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consent from the patient (or guardian if the patient was ,18 years
old) venous blood samples were taken. Cord blood samples were
obtained from consecutive deliveries in the Patan Maternity Ward
where consent was provided. Volunteers with pyrexia, or any
immune disorder were excluded. Sera were separated from clotted
whole-blood samples by centrifugation and frozen.
Hib ELISA
Serum anti-PRP antibody concentrations were determined
using a standard protocol [8,9]. Duplicate sample sera, initially
diluted 1:20, were re-tested at 1:200 and/or 1:2000 if necessary.
Statistical analysis
The mean concentration for each sample duplicate was log10-
transformed for calculation of the standard error of the geometric
mean concentration (GMC) [10]. Any sample below the lower
limit of detection (0.1 mg/ml) was given a value of 0.08 mg/ml for
the purpose of analysis. Samples were categorized as cord blood or
by age of participant in completed years. There is limited evidence
regarding the concentration of anti-PRP antibody required for
protection from invasive disease [11,12]. As in previous studies, we
used 0.15 mg/ml and 1 mg/ml of anti-PRP antibody as thresholds
for short- and long-term protection respectively [8,13,14].
Results
Seventy-one samples from participants aged 7 months to 77
years and 15 cord blood samples were analysed for anti-Hib (anti-
PRP) IgG. Participants were grouped by age into 6 groups: cord
blood (n= 15), 0.5–4 yrs (n = 15); 5–7 yrs (n = 15); 8–14 yrs
(n = 18); 15–54 yrs (n = 12); 55–77 yrs (n = 11). For each age
group the geometric mean antibody concentration (GMC) was
calculated together with the percentage of participants with
concentrations above the accepted correlates of ‘short-term’ (.
0.15 mg/ml) and ‘long-term’ (.1 mg/ml) protection (Fig. 1).
In the 0.5–4 year-olds the anti-PRP GMC and percentage
protected were low in relation to the pre-defined protective
thresholds; of note, no children in this age-group had an anti-PRP
concentration .1 mg/ml. The GMC and percentage with
antibody concentrations greater than the protective thresholds
were higher in 5–7 year-olds, with the majority of this age-group
(60%) having antibody levels .0.15 mg/ml. GMCs and percent-
ages with protective concentrations were higher still in 8–14 year-
olds, and highest in the 15–54 year-olds. In children up to 12
years-old 60% had anti-PRP antibody concentrations below the
threshold of detection in contrast to none of those participants
between the ages of 13 and 49 (data not shown). The GMC and
percentages with protective antibody concentrations were lower in
the over 55 age-group than in the 15–54 year-olds.
Discussion
To our knowledge, this is the first Hib seroepidemiological study
from Nepal. The general pattern of initially high anti-PRP
antibody concentrations from transplacentally transferred mater-
nal antibody, waning in early infancy, subsequent seroconversion
throughout childhood, and waning levels in the elderly, is
consistent with Hib seroepidemiological data reported in other
settings [15]. Previous studies have demonstrated the relationship
between anti-PRP antibodies and protection from invasive disease
[15]. It is presumed that anti-PRP antibody is acquired through
nasopharyngeal carriage of Hib or exposure to organisms
possessing antigens that are immunologically cross-reactive with
PRP. For any age cohort, the anti-PRP antibody concentrations
give an indication of the proportion of individuals susceptible to
Hib infection whilst the rate of acquisition of anti-PRP antibody
between age cohorts should reflect the degree of exposure to Hib
or cross-reactive antigens. In our study, 80% of children under 5
were serologically susceptible to invasive Hib disease with
concentrations of anti-PRP antibody below the threshold of
protection (,0.15 mg/ml). Even in late childhood, a substantial
proportion of individuals still did not have protective concentra-
tions of anti-PRP antibody (Fig. 1).
Anti-PRP Acquisition
Comparisons of antibody levels between different Hib seroep-
idemiological studies are limited by significant inter-laboratory
variability in the anti-PRP assay, and even between different labs
using the same anti-PRP ELISA [16]. It is therefore difficult to use
age-specific serology data to infer disease incidence. However, the
profile of anti-Hib antibody acquisition throughout childhood can
be compared and clearly differs between countries (see Supporting
Information, Figure S1 & Table S1, in File S1). Some studies find
that a low proportion of young children have protective
concentrations (.0.15 mg/ml) but a rapid increase in the
proportion of older children who are protected. For example, in
Burkina Faso whilst only 9% of children under 5 years of age had
concentrations .0.15 mg/ml, 75% of those aged 4–14 years were
protected [17]. This suggests a relatively high degree of exposure
to Hib in the under 5 s, and correlates with Hib meningitis
incidence data from Burkina Faso [18], and other African
countries, which suggest a high proportion of cases in infants,
and a high incidence in the under 5 s. Carriage data from West
Africa also support a high exposure to Hib in this region [19].
Seroepidemiological studies from some other regions, including
the UK [20], display a more gradual increase in the proportion
protected with increasing age. Overall, however, it is difficult to
identify a clear relationship between the different population
serologic profiles (Figure S1 & Table S1, in File S1) and either the
estimated incidence of Hib meningitis under 5, or the proportion
of Hib meningitis cases in infants [18]. Contributing factors that
may obscure a relationship between anti-PRP antibody and Hib
exposure are the variability in anti-PRP assays and the levels of
exposure to cross-reactive antigens [21]. Of all studies identified,
our data demonstrated one of the slowest rates of acquisition of
protection (,0.15 mg/ml), from 20% under 5 years of age, to 40%
in those aged 5–7 years, 67% in 8–14 year-olds, and 83% at 15–54
years. This suggests a relatively low level of Hib exposure
compared with that observed in other countries in the pre-vaccine
era.
Carriage
In populations with a known burden of invasive Hib disease,
reported carriage rates vary from 3 to 9% in children under 5 years
of age [22]. Such data for Nepal are sparse, but Williams et al.
reported a Hib carriage prevalence of 5% in children aged 3 months
to 12 years in the pre-vaccination era [4]. This is comparable to
countries such as the USA and UK [23,24], where disease incidence
has been sufficient to warrant routine immunization.
Disease incidence
Although there have been no population incidence data for
invasive Hib disease reported from Nepal, two studies prior to the
introduction of routine Hib immunisation from Kathmandu
demonstrated that Hib was the second most common cause of
meningitis in children after Streptococcus pneumoniae [25,26]. Hib was
identified in 25% of cases (n=77) of bacterial meningitis (with
established aetiology) in children under 5 [26], which is low
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compared with most studies globally, as meta-analysed by WHO
[18], but still indicative of a significant burden of disease. By infe-
rence, Hib pneumonia is likely to be prevalent but difficult to
demonstrate as cases are rarely bacteraemic [25,26]. Five South-East
Asian studies in the WHO analysis [18], and one of the studies from
Kathmandu [26], demonstrated a high proportion of total Hib
meningitis cases occurring in infancy. Although it has been sug-
gested that the proportion of infant cases is positively related to
overall disease incidence, the correlation is relatively weak, making
inferences about incidence unreliable for any individual country.
Limitations
The limitations of our study include the small sample size which
precludes a more detailed age-specific analysis of Hib immunity
acquisition in childhood, for example in those under 2 years who
would be expected to have impaired anti-PRP responses to natural
Hib exposure. There were only 5 children under 2, none of whom
had protective levels of antibody (.0.15 mg/ml). Also, the small
blood volumes in young children were insufficient to allow
comparisons of antibody avidity. Avidity has previously been
proposed as a biomarker for successful induction of immunological
memory, with increased avidity representing more functional
antibody [9]. Measuring antibody avidity may identify an effective
immunological memory (secondary to ‘natural priming’) in subjects
with low antibody concentrations [27]. Selection bias may have been
introduced by the hospital-based nature of this study, the patient
charges at Patan Hospital (although local medical staff consider that
the costs are not sufficient to deter attendance) [25], and the
attributes of patients willing to participate in a research study of this
kind. Finally the waning anti-PRP levels measured in the elderly may
reflect comorbidities, which were not solicited in this study.
Implications
The importance of Hib in Asia has previously been questioned.
However, our data suggest that at least 83% of the Kathmandu
population had been naturally exposed to Hib, or cross-reactive
antigens, before adulthood. Although our seroepidemiological
data are most compatible with a lower level of exposure to Hib
carriage, previous data on Hib carriage prevalence [4], and
meningitis aetiology [25,26] still indicate the importance of Hib
disease in Nepali children. Furthermore, we identified a relatively
prolonged period for which children are at risk of a disease for
which carriage and aetiological studies support a significant
burden of invasive illness, with the majority of children under 8
being susceptible to Hib. Now that a Hib conjugate vaccine is
included in the national immunization schedule, we would expect
Hib transmission to be low, through reduced acquisition amongst
vaccinees. Since this will in turn reduce the opportunity for natural
boosting of Hib antibody levels, ongoing serological surveillance
could be used to inform the need for booster doses of vaccine,
using data in this study as a baseline.
Supporting Information
File S1 Table S1 and Figure S1. Comparison of Hib
seroprevalance studies in the pre-vaccine era.
(DOC)
Figure 1. Mean Anti-Hib Antibody Concentrations and Percentage of Participants with Protective Levels. Only 20% of children under 5
years old have protective (.0.15 mg/ml) antibody levels, rising to 83% of 15–54 year-olds. Geometric mean anti-polyribosylribitol phosphate IgG
concentrations for each age group are plotted on the left y-axis (6SE). The percentage of participants with antibody concentrations .0.15 mg/ml
(‘short-term protection’: the height of the entire column) and.1 mg/ml (‘long-term’ protection: the height of only the shaded column) are plotted on
the right y-axis (6SE). Sample sizes (n): Cord Blood (n = 15); 0.5–4 yrs (n = 15); 5–7 yrs (n = 15); 8–14 yrs (n = 18); 15–54 yrs (n = 12); 55–77 yrs (n = 11).
doi:10.1371/journal.pone.0085055.g001
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